SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITEDSUCCESSFULLY LISTED ON HKEX
Latest Update:
3 rd March, 2021

On March 3, 2021, with product development and commercialization of integrated platform of biopharmaceutical company - SciClone Pharmaceuticals (Holdings) Limited.(" SciClone Pharmaceuticals "or the" company ", together with its subsidiaries, generally referred to as the "group", stock code: 6600, on the stock exchange of Hong Kong limited (" hkex ") is listed on the motherboard and start buying and selling.  

In the previous public offering, SciClone Pharmaceuticals 's initial offer of shares for sale was moderately oversubscribed, representing approximately 1,068.05 times the initial 11,599,000 shares available for sale in the Hong Kong Public offering. The offer was priced at HK $18.80 per share and was reasonably priced.  Net proceeds from the global offering were approximately HK $2,039.5 million (after deducting underwriting fees and commissions payable in connection with the global offering and estimated expenses assuming that the overallotment option was not exercised).  

Mr. Zhao Hong, executive Director, President and CEO of SciClone Pharmaceuticals (Holdings) Limited., said in an interview, "We are very grateful to investors from all walks of life for their enthusiastic support and interest in SciClone Pharmaceuticals Since its establishment, SciClone pharmaceutical has been taking patient health as its own responsibility, adhering to the culture of "strict compliance, high performance", and providing patients with high-quality products in line with international standards.  The company has strong commercialization capabilities, high standards of production and quality control, as well as a diversified drug pipeline, and is committed to solving the two unmet medical needs of oncology and severe infection through strong business and product development capabilities.  Today marks an important milestone for us as we enter the Hong Kong stock market and step onto the international capital stage.  In the future, we will continue to pursue two unmet medical needs in the treatment area, through effective life cycle management, continue to strengthen our marketing portfolio;  Optimize our pipeline by accelerating a fast-to-market strategy for late-stage assets and focusing on potential first-in-class or best-in-class early-stage assets;  Continue to innovate business models and enhance our commercialization and development capabilities;  Committed to talent development and enhancing our operational infrastructure to support our future expansion and deliver maximum returns to our shareholders and investors."  

 

About SciClone Pharmaceuticals (Holdings) Limited.  

SciClone Pharmaceuticals (Holdings) Limited. is a biopharmaceutical company with an integrated platform for product development and commercialization that is strategically focused on some of the largest and fastest-growing unmet medical needs in China, including oncology and critical infections.  With the strength of product development and commercialization, The company aims to develop and commercialize high-quality listed products and combinations of products under development in key therapeutic areas. 

Latest Update:
3 rd March, 2021